title: Sensitivity to taxoid derivatives of a newly established human endometrioid ovarian adenocarcinoma radioresistant cell line.
abstract: An endometrioid ovarian adenocarcinoma cell line CAVEOC-2 was characterized. Maintained in monolayered culture, CAVEOC-2 cells exhibited a 33-hr doubling time. When xenografted into nude mice, these cells produced fast growing tumors. Colony-forming efficiency in agar was 50%. DNA index was 1.5 and cytogenetic analysis showed a triploid karyotype. CAVEOC-2 cells did not express mdr-1 gene and were chemosensitive to doxorubicin (IC50 = 1.82 +/- 0.76 mumol/l), paclitaxel (IC50 = 3.33 +/- 0.26 nmol/l) and docetaxel (IC50 = 0.68 +/- 0.28 nmol/l), while they showed an intermediate sensitivity to cisplatin (IC50 = 9.40 +/- 1.02 mumol/l). CAVEOC-2 cells seemed highly radioresistant (SF2 = 0.81, alpha = 0.02 Gy-1, beta = 0.025 Gy2, and MID = 4.31 Gy). Activities of glutathione S transferase and gamma-glutamyl transpeptidase were respectively 23.5- and 3.4- fold higher than those of sensitive A2780 cell line. These characteristics make the CAVEOC-2 cells a suitable model for the study of human endometrioid ovarian adenocarcinoma.
authors.affiliation: Laboratoire de Recherche en Oncologie, Centre Alexis Vautrin, Vandoeuvre-Less-Nancy, France.
authors.forename: G
authors.initials: G
authors.lastname: Griffon
authors.forename: J L
authors.initials: JL
authors.lastname: Merlin
authors.forename: R M
authors.initials: RM
authors.lastname: Parache
authors.forename: N
authors.initials: N
authors.lastname: Martinet
authors.forename: S
authors.initials: S
authors.lastname: Marchal
authors.forename: F
authors.initials: F
authors.lastname: Nabet
authors.forename: M
authors.initials: M
authors.lastname: Wellman
authors.forename: C
authors.initials: C
authors.lastname: Barlier
authors.forename: C
authors.initials: C
authors.lastname: Marchal
mesh_terms: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000235:genetics; D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology*; D001483:Base Sequence; D018269:Carcinoma, Endometrioid / Q000188:drug therapy* / Q000473:pathology* / Q000532:radiotherapy; D002455:Cell Division / Q000187:drug effects; D004273:DNA, Neoplasm / Q000032:analysis / Q000235:genetics; D000077143:Docetaxel; D004317:Doxorubicin / Q000494:pharmacology; D004354:Drug Screening Assays, Antitumor; D005260:Female; D005434:Flow Cytometry; D015870:Gene Expression; D005979:Glutathione Peroxidase / Q000378:metabolism; D005982:Glutathione Transferase / Q000378:metabolism; D006801:Humans; D007150:Immunohistochemistry; D007621:Karyotyping; D051379:Mice; D008819:Mice, Nude; D008875:Middle Aged; D008969:Molecular Sequence Data; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology* / Q000532:radiotherapy; D017239:Paclitaxel / Q000031:analogs & derivatives / Q000494:pharmacology; D011003:Ploidies; D012333:RNA, Messenger / Q000378:metabolism; D011836:Radiation Tolerance; D043823:Taxoids; D014407:Tumor Cells, Cultured; D005723:gamma-Glutamyltransferase / Q000378:metabolism
chemical_list: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000972:Antineoplastic Agents, Phytogenic; D004273:DNA, Neoplasm; D012333:RNA, Messenger; D043823:Taxoids; D000077143:Docetaxel; D004317:Doxorubicin; D005979:Glutathione Peroxidase; D005723:gamma-Glutamyltransferase; D005982:Glutathione Transferase; D017239:Paclitaxel